Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The colchicine-binding site is located primarily within the β-subunit of tubulin, at the interface with the α-subunit in the αβ-tubulin heterodimer. This site is a major target for small-molecule inhibitors that disrupt microtubule dynamics, making it highly relevant for anticancer drug development. Binding of inhibitors prevents tubulin from adopting the straight conformation necessary for microtubule assembly, leading to depolymerization, cell cycle arrest, and apoptosis. Many structurally diverse compounds can bind here—these are collectively termed "colchicine-binding site inhibitors" (CBSIs). CBSIs are under active investigation as anticancer and antiparasitic agents.
Inhibition of tubulin polymerization by binding to the colchicine-binding site, leading to microtubule destabilization and cell cycle arrest.
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Colchicine-Binding Site on Tubulin (CBSI).